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Background: Treatment for locally advanced rectal cancer (LARC) consists of chemoradiation therapy (CRT) and
surgery. Approximately 15% of patients show a pathological complete response (pCR). Increased pCR-rates can be
achieved through dose escalation, thereby increasing the number patients eligible for organ-preservation to improve
quality of life (QoL). A randomized comparison of 65 versus 50Gy with external-beam radiation alone has not yet been
performed. This trial investigates pCR rate, clinical response, toxicity, QoL and (disease-free) survival in LARC patients
treated with 65Gy (boost + chemoradiation) compared with 50Gy standard chemoradiation (sCRT).
Methods/design: This study follows the ‘cohort multiple randomized controlled trial’ (cmRCT) design: rectal cancer
patients are included in a prospective cohort that registers clinical baseline, follow-up, survival and QoL data. At
enrollment, patients are asked consent to offer them experimental interventions in the future. Eligible patients—
histologically confirmed LARC (T3NxM0 <1 mm from mesorectal fascia, T4NxM0 or TxN2M0) located ≤10 cm from
the anorectal transition who provided consent for experimental intervention offers—form a subcohort (n = 120).
From this subcohort, a random sample is offered the boost prior to sCRT (n = 60), which they may accept or refuse.
Informed consent is signed only after acceptance of the boost. Non-selected patients in the subcohort (n = 60)
undergo sCRT alone and are not notified that they participate in the control arm until the trial is completed.
sCRT consists of 50Gy (25 × 2Gy) with concomitant capecitabine. The boost (without chemotherapy) is given prior
to sCRT and consists of 15 Gy (5 × 3Gy) delivered to the gross tumor volume (GTV). The primary endpoint is pCR
(TRG 1). Secondary endpoints include acute grade 3–4 toxicity, good pathologic response (TRG 1-2), clinical
response, surgical complications, QoL and (disease-free) survival. Data is analyzed by intention to treat.
Discussion: The boost is delivered prior to sCRT so that GTV adjustment for tumor shrinkage during sCRT is not
necessary. Small margins also aim to limit irradiation of healthy tissue. The cmRCT design provides opportunity to
overcome common shortcomings of classic RCTs, such as slow recruitment, disappointment-bias in control arm
patients and poor generalizability.
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Table 1 Inclusion and exclusion criteria for the RECTAL
BOOST studya
Inclusion criteria Exclusion criteria
Participant in the PICNIC project Metastatic disease
Informed consent obtained







Prior radiation to the pelvis
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Colorectal cancer is the second most common cancer in
women and third in men worldwide [1]. Almost one-
third of Dutch colorectal cancers are located in the rec-
tum [2]. Rectal cancers are treated by surgery, preceded
by chemoradiation in case of locally advanced rectal can-
cer (LARC). Chemoradiation consists of a total dose of
about 50 Gy combined with capecitabine. With this
treatment regimen, approximately 15% of patients show
a pathological complete response (pCR) [3,4], classified
by Mandard et al. as tumor regression grade 1 (TRG 1)
[5]. In a recent meta-analysis, we showed that doses of
≥60 Gy were associated with an increased pCR rate to
20.4%, without compromising toxicity [6].
Patients with ‘good’ clinical response, either pCR (TRG
1) or near-pCR (TRG 2), might be eligible for organ-
preserving approaches. The aim of these strategies is to
deliver an optimal quality of life (QoL) without com-
promising the oncologic outcome in this favorable sub-
group. Recently, several protocols have been developed,
that use either local excision [7-9] or a “watch-and-wait”
policy [10-12], in order to omit surgery (total mesorectal
excision) as the primary treatment. In addition, patients
who reach a pCR often show reduced local recurrence
and improved (disease-free) survival probabilities com-
pared with patients with a poor response (TRG 3–5)
[3,13-15], possibly driven by a favorable tumor biology.
Thus, by escalating the preoperative radiation dose,
the amount of patients with a ‘good’ clinical response or
pCR who are eligible for organ-preserving treatment can
potentially be increased. However, response rates after
high-dose external radiation with 65 Gy have not yet
been investigated in a randomized setting. Therefore, we
set up an exploratory trial, the RandomizEd Controlled
Trial for Pre-operAtive Dose-escaLation BOOST in
Locally Advanced Rectal Cancer (RECTAL BOOST
study: ClinicalTrials.gov NCT01951521) to compare
tumor pCR rates (TRG 1), pathologic ‘good’ responses,
toxicity levels, clinical tumor response and QoL between
patients treated with 65 Gy chemoradiation (15 Gy boost
plus 50 Gy chemoradiation) and those treated with
50 Gy standard chemoradiation therapy (sCRT).within the PICNIC project
Tumor distance of ≤10 cm
from anorectal transition
Inadequate understanding
of the Dutch language in
speech and/or writing
Indication for chemoradiation
based on Dutch guidelines
Recent pregnancy ≤1 yr ago




At least one contraindication
for capecitabine administration
aRECTAL BOOST, RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation
BOOST in Locally Advanced Rectal Cancer; PICNIC, ProspectIve data CollectioN
Initiative on Colorectal cancer; MRI, Magnetic resonance imaging.Methods/design
Study design
This study is being conducted within the ProspectIve
data CollectioN Initiative on Colorectal cancer (PICNIC)
project [16]. The prospective observational PICNIC cohort
includes patients with colorectal cancer of all stages. Infor-
mation collected includes baseline demographic and clin-
ical data, as well as prospective clinical follow-up and
patient-reported outcome measures (PROMs). The study
follows the cohort multiple randomized controlled trial(cmRCT) design [17] and provides a pragmatic infrastruc-
ture for multiple randomized controlled trials (RCTs).Patient recruitment
At enrollment in the PICNIC cohort, patients are asked
to provide informed consent for prospective collection
of clinical, survival and PROMs data. In addition, ac-
cording to the cmRCT design, we ask patients’ consent
to be randomly selected to receive offers on experimen-
tal interventions in the future and to use their data com-
paratively within the context of the PICNIC project.
From among the PICNIC cohort, we will identify all
patients eligible for the boost intervention based on the
following inclusion criteria: (1) histologically confirmed
LARC, defined as T3 with threatened mesorectal fascia
(<1 mm), T4 or N2M0 [18] (based on Dutch guidelines for
chemoradiation in rectal cancer [19], in which N2 is de-
fined as ≥4 positive nodes visible with diameter >9 mm or
5 to 9 mm combined with 2 of the following 3 characteris-
tics: irregular border, heterogeneous or round-shaped); (2)
tumor located ≤10 cm from the anorectal transition; and
(3) previously obtained informed consent to be randomly
offered experimental interventions within the context of
the PICNIC project (Table 1). Patients are ineligible in case
of inflammatory bowel disease, pregnancy, previous radi-
ation to the pelvis, contraindication for capecitabine and
inadequate comprehension of the Dutch language in
speech and/or writing. Female patients in whom the tumor
is located on the anterior wall close to the vagina are also
ineligible because the maximum tolerated dose to the
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is in proximity to it.
Random selection
Patients within the PICNIC cohort who meet the above
inclusion criteria form a subcohort of eligible patients
(Figure 1). From among this subcohort, a random sample
is selected on a 1:1 basis with varying block sizes (n = 6
to 8) using a centrally available computer program. Ran-
domly selected patients are offered the experimental inter-
vention (boost prior to sCRT) by their treating physician.
If they accept the offer, they will sign an additional in-
formed consent to receive the boost. Patients who refuse
the boost will receive care as usual (that is, sCRT). Patients
in the subcohort who will not be randomly selected will
not be informed about the boost intervention, nor will
they be informed about their participation in the control
arm of this study. When the trial is completed, aggregate
disclosure about the trial results will be provided to the
entire PICNIC cohort at the same time.
Standard treatment
sCRT consists of 50 Gy (25 × 2 Gy on weekdays) com-
bined with capecitabine. The radiation dose is delivered
by intensity-modulated radiation therapy (IMRT), which is
standard care in our hospital, to the planned target volume
(PTV), which comprises the gross tumor volume (GTV)
and clinical target volume (CTV). Target volumes are de-
lineated on computed tomography (CT) scans, matched
to- and combined with T2- and diffusion-weighted mag-
netic resonance imaging (DWI) according to published
guidelines [20]. The CTV follows the mesorectal fascia up
to the rectosigmoid curvature and stretches maximally to
4 cm caudal from the tumor, sparing the sphincter in case
of a low anterior resection (LAR), or includes theFigure 1 Study design and flowchart. PICNIC, ProspectIve data Collectio
Controlled Trial for Pre-operAtive Dose-escaLation BOOST in Locally Advancsphincter complex +1-cm margin in case of an abdomino-
perineal resection (APR). The lymph node regions (in-
ternal iliac and obturator) stretch from the caudal end of
the v. iliaca communis downward to the crossing of the
internal iliac vessels under the m. piriformis, laterally lim-
ited by the pelvic muscles. The obturator region stretches
from the m. obturatorius to the m. levator, ventrally lim-
ited by the ureter or dorsal side of the neurovascular bun-
dle without inclusion of the vesiculae, uterus and vagina.
Lateral and dorsal border are marked by the pelvic mus-
cles and ventral iliac region. In addition, the presacral re-
gion stretches from the upper level of the iliac vessels to
mesorectum, ventrally limited 2 cm from the sacrum, in-
cluding the a. rectalis superior and excluding the neurofor-
amina. The PTVCTV50 is a non-uniform margin around
the CTV according to local protocol consisting of an ex-
pansion of 13 mm ventrally, 9 mm dorsally, 10 mm lat-
erally and 10 mm craniocaudally (Figure 2). The prescribed
dose to the PTVCTV50 is that 95% of the prescribed dose
should cover ≥99% of the PTV. Radiation is delivered with
an external beam linear accelerator. For position verifica-
tion, the sCRT protocol consists of cone-beam CT prior to
the first three fractions and weekly thereafter.
Capecitabine is administered orally twice daily on
treatment days at a dose of 825 mg/m2, taken 2 hours
before each radiation fraction and 12 hours later.
Hematologic toxicity is tested every 2 weeks. Surgery is
performed 10 to 12 weeks postradiation according to the
Dutch guidelines [19]. The decision whether to perform
total mesorectal excision surgery in form of LAR or
APR, is made on the basis of the location and extensive-
ness of the tumor [21].
Two routine MRI scans are acquired using an MRI
protocol developed in house, consisting of T2-weighted
and DWI image sequences [22]. The first scan (takenN Initiative on Colorectal cancer; RECTAL BOOST, RandomizEd
ed Rectal Cancer.
Figure 2 Cumulative dose plan of boost plus standard chemoradiation fractions (left) with associated dose volume histogram (right).
Delineations of gross tumor volume (GTV) plus planned target volume (PTVGTV) (red), clinical target volume (CTV) plus PTV (PTVCTV) (green), bladder (brown)
and sigmoid (pink). Areas that receive a total dose of >65 Gy are represented in orange), and those that receive >50 Gy are shown in turquoise.
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ation planning, and the second (obtained 9 weeks post-
radiation) is used for preoperative response evaluation
and surgical planning. Immediately prior to surgery, the
surgeon will also perform a digital rectal examination
(DRE) for clinical response evaluation.
Boost intervention
The experimental boost intervention consists of 15 Gy
(5 × 3 Gy on weekdays) to the GTV without concomitant
chemotherapy. The boost is delivered in the week prior to
the start of sCRT. A cumulative GTV dose of 65 Gy is de-
livered over the full treatment course of 30 fractions
(6 weeks). This results in an equivalent dose in 2-Gy frac-
tions of 66.3 Gy (α/β = 10 Gy) [23]. GTV delineation is
based on T2-weighted and DWI scans; no CTVGTV65
margin is applied; and the PTVGTV65 is defined by a non-
uniform margin of +11 mm in the anteroposterior direc-
tion, +7 mm in the lateral direction and +13 mm in the
craniocaudal direction around the GTV, which represents
tumor movement that was observed on in-house daily
MRI scans and setup errors [24]. A volumetric modulated
arc therapy stereotactic treatment plan is generated for
boost patients, whereas IMRT is standard care used in the
control arm, that accumulates the boost and standard che-
moradiation doses (Figure 2). The maximally allowed cu-
mulative dose within the GTV is 80 Gy (123% of 65 Gy),
and the volume receiving 95% of the prescribed dose
should be larger than 99% of the PTVGTV65. The max-
imum dose around, and dose prescription to, the
PTVCTV50 is similar to the elective sCRT field (that is,
53.5 Gy). Daily online cone-beam CT scans are used for
positioning before each boost fraction, and the sCRT pos-
ition verification protocol follows thereafter.
Organs at risk (OARs) consist of the bowel bag (ex-
cluding sigmoid), bladder, vagina and anal sphincter.The dose constraints for the OARs remain unchanged
for boost patients (namely, the dose to 1 cc of the OARs
should be ≤53.5 Gy), and the volume receiving 45 Gy is
aimed to be less than 195 cc for the bowel bag (exclud-
ing the sigmoid). OAR constraints are leading over
PTVGTV65 coverage and may thus limit GTV dose if ne-
cessary. If dose prescriptions cannot be reached, a panel
of radiation oncologists will discuss the feasibility and
anticipated safety of the treatment plan and decide ei-
ther to continue or to adapt the plan toward acceptable
OAR constraints, taking into account anatomical limita-
tions and planned surgery. One additional MRI scan is
obtained in patients who receive the boost for response
prediction purposes at the end of the second week (after
ten fractions including the five boost fractions) and a
rectoscopy for clinical response evaluation is performed
in a subgroup of boost-arm patients that showed a ‘good’
response based on MRI.
Primary endpoint
The primary endpoint of this study is pCR, which is
classified according to the Mandard classification system
as tumor regression grade 1 (TRG 1) [5] (that is, a sterile
specimen with absence of residual cancer cells). Experi-
enced gastrointestinal pathologists use a standardized
protocol to evaluate the specimens [25], and central re-
view of pathology is performed.
Secondary endpoints
Secondary endpoints include non-complete pathologic
responses (TRG 2–5), acute grade 3–4 toxicity, clinical
response, surgical complications, QoL and disease-free
and overall survival. The non-complete pathologic re-
sponses are categorized as good (TRG 1–2) or ‘not good’
(TRG 3–5) by the pathologist. A radiation oncologist
will assess toxicity at weekly visits during the radiation
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pletion of sCRT. Toxicity is recorded according to the
National Cancer Institute’s Common Terminology Cri-
teria for Adverse Events, version 4.03 [26]. Long-term
toxicity, (serious) adverse events (SAEs), hospitalization
and other health-related problems are registered within
the context of the PICNIC cohort during clinical follow-
up and annual patient-administered questionnaires on
health and oncological status. Clinical response evalu-
ation is based on MRI (9 weeks after completion of che-
moradiation; that is, the week before surgery) and DRE
and rectoscopy, which are both performed right before
surgery while the patient is under anesthesia. MRI and
DRE are standardly performed in all patients, whereas
rectoscopy is only performed in intervention arm pa-
tients who showed a good response based on MRI. For
the MRI, a combination of T2-weighted and DWI se-
quences is used to measure residual tumor tissue in the
initially delineated tumor region and its surrounding
elective radiation field. Surgical complications are regis-
tered up to 30 days after the primary surgery in all pa-
tients and after closure of the diverting stoma in patients
who previously underwent a LAR. For safety reasons, oc-
currence of anastomotic leakage is monitored closely in
the LAR subgroup by daily review of postoperative pa-
tient charts for 30 days. QoL data are recorded by means
of either online forms (Patient-Reported Outcomes Fol-
lowing Initial treatment and Long-term Evaluation of
Survivorship (PROFILES): http://www.profilesregistry.nl/
) or pencil-and-paper questionnaires. For this purpose,
cancer-specific QoL questionnaires from the European
Organization for Research and Treatment of Cancer
(EORTC) are used, including the core (QLQ-C30 [27])
and colorectal cancer-specific (QLQ-CR29 [28,29]) ques-
tionnaires. The EORTC QLQ-C30 covers five functional
scales, three symptom scales, a global QoL scale and six
single items. The EORTC QLQ-CR29 assesses urinary,
bowel and/or stoma, psychological and sexually related
QoL issues, as well as side effects due to chemotherapy.
These questionnaires are provided at the time of diagno-
sis (baseline) and 3, 6, 12, 18 and 24 months thereafter.
Survival and disease-free survival are monitored within
the PICNIC project through clinical follow-up records
and via a link with the Dutch Cancer Registry. Disease-
free survival is defined as the time in absence of a rectal
cancer local recurrence or metastasis.
Safety
According to Dutch law, the investigator reports SAEs
within 15 days following notification through a government-
based internet portal (Centrale Commissie Mensgebonden
Onderzoek (Central Committee on Research Involving
Human Subjects): https://www.toetsingonline.nl/) to the
accredited institutional review board (IRB) that approvedthe protocol. SAEs that result in death or are life-
threatening will be reported within 7 days.
Because this is an exploratory dose escalation study,
an independent data and safety monitoring board
(DSMB) will make recommendations on continuation of
the study based on safety results, focusing on toxicity
and anastomotic leakage. The DSMB consists of an ex-
pert surgeon, a radiation oncologist and a statistician
and is provided, annually or after every SAE, with the
raw data on the primary and secondary outcomes (in-
cluding toxicity, surgical complications and survival).
After the first 10 patients with LAR have undergone
boost treatment, inclusion of patients scheduled for LAR
will be stopped for 8 months to let the DSMB compare
anastomotic leakages between boost and control arms.
The 8-month period will consist of the time between
sCRT to primary surgery (10–12 weeks) followed by the
time between primary surgery and bowel reconstruction,
including a postoperative monitoring period (16–20
weeks). Only inclusion of patients undergoing LAR will
be halted during this stop, because patients undergoing
APR have no risk of anastomotic leakage, owing to their
permanent stoma. The DSMB analyzes the data inde-
pendently of the investigators and reports their advice
on continuation of the study to the sponsor, which will
decide on continuation or stopping of the study.
Sample size considerations
On the basis of our center’s experience, we assume that
13% of patients will reach pCR if undergoing sCRT. On
the basis of a prediction model published by Appelt
et al. [30], we expect the pCR rate to be 30% after 65 Gy
treatment. Because we consider this study to constitute
preliminary work for subsequent studies aimed at evalu-
ating even higher dose increases, we deem it important
to find an effect if there really is one, but less important
to unjustly find an effect. Therefore, we will use a one-
sided α of 15% because it is unlikely that the pCR rate
after boost treatment plus sCRT will be lower than after
sCRT alone, in combination with a power of 80% be-
cause we do not want to increase uncertainty when a
negative result is achieved. We further expect that ap-
proximately 80% of the patients who receive a boost offer
will accept it. Patients who are offered the boost treatment
but refuse to undergo the boost will remain in the inter-
vention arm for analysis but receive sCRT (Figure 1). We
expect no cross-over from the control arm to the inter-
vention arm, because only patients who are randomly se-
lected to receive a boost offer are informed about and
offered it, whereas all non-selected patients undergo
standard treatment (that is, sCRT) without receiving infor-
mation about the boost trial. Taking into account the esti-
mated response rates, together with a 20% refusal rate in
the intervention arm, we require 60 patients per arm to
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pect to complete recruitment within 3 years.
Data analysis
Data will be analyzed according to the intention-to-treat
principle. Data of eligible patients who were randomly
offered the boost (intervention arm) will be compared
with eligible patients who were not randomly selected
(control arm). In case of dropout (that is, no surgery fol-
lowing chemoradiation), a worst-case analysis will be
performed in which all non-resected intervention-arm
patients are classified as non-complete responders and
all non-resected control patients are classified as
complete responders. However, because omission of sur-
gery is not common practice in our institution, we ex-
pect these numbers to be small. In case of substantial
boost treatment refusal in the intervention arm, com-
plier average causal effect analysis will be performed to
deal with differences in compliance with treatment be-
tween both arms [31]. Outcomes include tumor pCR
rate (TRG 1), good pathological response (TRG 1–2),
clinical response, grade 3–4 toxicity, QoL, recurrence
rates and disease-free and overall survival.
The primary outcome (proportion of patients with
pCR) will be presented in proportions and compared by
means of the χ2 test. Toxicity will be presented as the
overall and/or time point-specific incidence of grade 3–4
toxicity, and differences will be tested with the χ2 test.
QoL will be compared at multiple points in time. A rele-
vant change in the patient’s perspective is indicated by a
10% difference or more than 0.5 of the standard devi-
ation [32]. QoL data will be analyzed by mixed-effects
models. Differences in disease-free and overall survival
rates will be analyzed by Kaplan-Meier analysis and log-
rank test. Differences with a P-value <0.05 are consid-
ered statistically significant, except for the primary
endpoint, where P < 0.15 has been prespecified.
Ethical approval
IRB approval was obtained separately for both the PIC-
NIC project (including the cmRCT infrastructure) and
the RECTAL BOOST study from the ethical body of the
UMC Utrecht (under reference numbers 12/510 and 13/
522, respectively). The PICNIC project is published
under NCT02070146 [16] and the RECTAL BOOST
study under NCT01951521 [33] on ClinicalTrials.gov.
Discussion
The RECTAL BOOST study aims to quantify the effect of
an external beam radiation (EBR) boost of 15 Gy prior to
standard chemoradiation (50 Gy) on pCR rates in patients
with locally advanced rectal cancer. Toxicity, clinical
(complete) response, (surgical) complications, (disease-
free) survival, QoL and feasibility of boost delivery aresecondary endpoints. In this study, we will assess in a ran-
domized fashion whether a preoperative 65 Gy EBR-only
regimen (15 Gy boost followed by 50 Gy chemoradiation)
can safely increase the proportion of patients with pCR
(TRG 1) in comparison with the proportion observed after
50 Gy chemoradiation alone. Although contact X-ray [34],
brachytherapy, EBR and EBR-brachytherapy combined
studies [6] have shown response, sphincter-saving and
organ preservation benefits at doses up to 60 Gy, such
benefits have not been shown for the 65 Gy dose level
when reached by an EBR-only approach.
High rates of good responders are important, as this
will increase the number of patients eligible for organ-
preserving treatment strategies. These strategies aim to
improve the QoL of patients with a good response while
their good oncologic outcome, and possible survival
benefits, are maintained. Nevertheless, the value of
tumor regression has not yet been confirmed as a surro-
gate endpoint for oncologic outcome in this setting. In
the present study, however, all patients, including those
with a good clinical response to preoperative treatment,
will still undergo surgery because pathological response
is the primary endpoint, and because resection remains
the standard care according to Dutch guidelines [19].
Therefore, future randomized studies in patients with
good clinical responses after (boost) chemoradiation are
needed to further assess the effect of radical surgery ver-
sus organ preservation on QoL, toxicity and (disease-
free) survival. In this study, we aim to quantify response
rate by its current gold standard (that is, pathology),
which in turn can be correlated to the clinical response
data that are also obtained. In so doing, this study will
provide important insight into the results of dose escal-
ation that would otherwise be lacking in a trial that
would combine dose escalation and omission of surgery
within the same trial.
In this study, we choose to deliver the boost prior to
chemoradiation to obtain maximal tumor visibility in
order to avoid dose administration to healthy tissue. The
rationale underlying this is that GTV deformation is
likely to occur during sCRT as a result of tumor shrink-
age, and because the induced inflammatory reaction re-
sults in edema which hinders adequate GTV definition.
Both factors make imaging and delineation of the tumor
more difficult and less reliable thereby likely to result in
overestimation of the remaining GTV. When larger
areas would then incorrectly be irradiated, surrounding
healthy tissue might receive a higher dose than planned.
On the basis of our own data on patients receiving 5 ×
5 Gy radiation within one week, we know that tumor
shrinkage does not yet occur during the first week of radi-
ation, which implies that GTV delineations made prior to
irradiation remain adequate throughout the first week of
(chemo)radiation. This allows a single GTV delineation to
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sCRT. Furthermore, we choose to use IMRT because
this is the standard of care in our hospital, and this
study is set up as a single-facility trial. Direct applicabil-
ity of these results should thus be considered when ex-
trapolated to other centers in which different radiation
techniques are used.
We have chosen to apply the cmRCT design, which
aims to overcome common shortcomings of classic
RCTs, such as slow recruitment, disappointment bias
in patients randomized to the control arm, and poor
generalizability. Not uncommonly, oncological patients
possess strong preferences for experimental treatments
that are (often) falsely regarded to be superior. This
prevents such patients from taking part in randomized
studies, thereby diminishing recruitment rates for
RCTs. Furthermore, patients who remain willing to
participate in RCTs often represent a younger, health-
ier, higher-educated subgroup, and once participating,
these patients are unfortunately often allowed to par-
ticipate in only one trial at a time. All this makes re-
cruitment for RCTs difficult and prone to selection
bias. Because the cmRCT design uses a cohort as a re-
cruitment pool, it represents the routine population
more adequately because cohort inclusion is generally
less selective. Because this baseline may also evolve
over time, the cmRCT furthermore provides the advan-
tage that the effectiveness of experimental interven-
tions is compared with the most up-to-date available
standard care with which it should compete, instead of
competing with outdated treatments which is often the
case when classic RCTs are published. A new aspect
brought by the cmRCT design is that it provides the
opportunity to evaluate acceptance rates of offered
treatments. This offers new insights into patient pref-
erences and reasons for refusal of experimental inter-
ventions that become increasingly important. It forces
clinicians and researchers to rethink their treatment
approach at a much earlier stage when, for instance, a
large proportion of patients declines the offered treat-
ment. Overall, efficient, less selective recruitment, col-
lection of long-term outcomes and early preference
monitoring could reduce research costs significantly
when conducting RCTs within the cmRCT design.
The RECTAL BOOST study is a pragmatic RCT per-
formed within the infrastructure of the cmRCT design,
that aims to quantify the effect on pCR rate of preopera-
tive dose escalation to 65 Gy in comparison with stand-
ard 50 Gy chemoradiation in patients with locally
advanced rectal cancer. If the proportion of good re-
sponders can be increased by dose escalation, this strat-
egy could provide an option to increase the number of
patients that may benefit from organ-preserving strat-
egies in the future.Trial status
Ethical approval for this trial was obtained in June 2014.
Recruitment started in September 2014 and is currently
ongoing.
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